Harvard Business Review

OCTOBER 24, 2014

In addressing the billion-dollar adherence problem, Vitality (since acquired by NANTHEALTH ) considered the interests of the players in the diverse ecosystem, including pharmaceutical companies, retail pharmacies, and health care providers. Operations. It also took into account their roles in changing patient behavior. Human resources.

Productivity 8

Productivity Products Company Engineering 8

Harvard Business Review

OCTOBER 20, 2016

As a practical matter, for example, these changes in the global policy regime are forcing multinational corporations to scale back and sell parts of their international operations. Meanwhile the Institute of International Finance forecasted net capital flows for emerging markets in 2015 would be negative for the first time since 1988.

Globalization 8

Globalization Banking Policies Politics 8

Harvard Business Review

APRIL 19, 2016

Imagine the changes afoot in the pharmaceutical, medical device, automotive, and consumer electronics industries. Each of the potential business benefits of 3D printing carries tax implications that could alter the equation for any anticipated operating efficiency or return on investment. Are there operations you would shed?

Supply Chain 8

Supply Chain Execution Analysis Technology 8

Harvard Business Review

AUGUST 2, 2011

In reality, each country needs the other to succeed in order to thrive — to finance growth, secure export markets, train talent, transfer technology, and more. For example, pharmaceutical firms license compounds to each other and co-promote products in different markets. Facilitate discussion between competitors.

Apparel 14

Apparel Pharmaceuticals Finance Licensing 14

Harvard Business Review

NOVEMBER 9, 2011

COOs are relatively common in service industries such as financial services, energy, information technology and telecommunications, but in manufacturing sectors — such as automotive, chemical, and pharmaceutical companies — they are relatively rare. What do you think?

COO 11

COO Sample Telecommunications Automotive 11

Harvard Business Review

JUNE 8, 2015

Pharmaceutical companies, buffeted by regulatory changes, new drug technologies that alter entry barriers and competition, price pressures, and an estimated 300,000 job cuts since 2000, seem to fit the popular narrative of large organizations unable to deal with disruptive forces.

Health Care 8

Health Care Venture Capitalist Strategic Fit Pharmaceuticals 8

Harvard Business Review

SEPTEMBER 19, 2016

Imagine, for example, that you’re a pharmaceutical CEO deciding whether to recall a new drug. From a historical perspective, the idea that managers in organizations have a single, dominant duty — to achieve or maximize economic returns — is a striking development. How should you make this decision?

ROI 8

ROI Long-term Conflict of Interest Pharmaceuticals 8

Harvard Business Review

OCTOBER 25, 2018

The superstars tend to be more involved in global flows of trade and finance, more digitally mature, and they dominate the lists of the most valued companies, the most valued brands, the most desirable places to work, and the most innovative companies. The link between superstar firms, sectors, and cities is complex.

Industry 9

Industry Company GDP Bottom-up 9

Harvard Business Review

JUNE 20, 2017

Multinational companies operating in Mexico are facing a great deal of uncertainty. Firms in innovation-driven industries, such as pharmaceuticals and medical devices, have long supported greater standardization across borders, with stronger intellectual property protections and enforcement of regulatory standards. Renegotiating NAFTA.

Supply Chain 8

Supply Chain Depreciation Uncertainty Marketing 8

Harvard Business Review

MAY 5, 2016

Within weeks there was $50 billion in business deals involving foreign companies, including the Airbus agreement (worth $25 billion) to sell 118 planes, and Italy’s state rail company’s $5 billion pact to develop the local rail network. sanctions are delaying these projects being financed. However, remaining U.S.

Tourism 8

Tourism Banking Due Diligence Hotels 8

Harvard Business Review

AUGUST 23, 2016

Boards of companies operating in the consumer discretionary industry have a disproportionately high representation of Democrats, while boards operating in the industrials and energy and utilities industries skew more Republican. Both Republicans and Democrats say the most effective board committee is audit/finance.

Politics 8

Politics Committee Telecommunications Diversity 8

Harvard Business Review

NOVEMBER 10, 2017

Spending on corporate learning, particularly leadership development, continues to increase at a staggering pace. According to one piece of research , spending on frontline leadership development alone increased by over 310% in a three-year period. Pat Canova/Getty Images. Insight center. The Gap Between Strategy and Execution.

Skills 8

Skills Agility Learning-by-Doing Content 8

Harvard Business Review

FEBRUARY 24, 2015

The first category is exogenous factors over which the business has little control: the growth of the markets into which it sells; the competitive intensity and thus the average profitability of the industry in which it operates; or the fragmentation of its industry and thus the scope for a growth-by-acquisition approach.

Chemicals 8

Chemicals How To Kahneman Reputation 8

Harvard Business Review

MAY 15, 2013

Nor can we develop good approaches to analyzing, preserving and transforming cultures. If we can define what organizational culture is , it gives us a handle on how to diagnose problems and even to design and develop better cultures. finance vs. marketing) and units (e.g. The cultures of organizations are never monolithic.

Incentives 8

Incentives Definition Pharmaceuticals System 8

Harvard Business Review

FEBRUARY 4, 2013

Levi Strauss, intriguingly, has used biomimetic techniques in developing new production techniques for jeans. Perhaps surprisingly, two leading examples come from pharmaceutical companies. Breakthrough Finance. Breakthrough Access. Breakthrough involves a shift to new types of impact investment.

EPS 8

EPS Innovation CEO Pharmaceuticals 8